The Current Ratio as of November 2024 (TTM) for Immuneering Corporation (IMRX) is 9.39

According to Immuneering Corporation’s latest financial reports and current stock price. The company's current Current Ratio is 9.39. This represents a change of -29.14% compared to the average of 13.25 of the last 4 quarters.

Immuneering Corporation (IMRX) Historical Current Ratio (quarterly & annually)

How has IMRX Current Ratio performed in the past?

The mean historical Current Ratio of Immuneering Corporation over the last ten years is 19.29. The current 9.39 Current Ratio has changed 4.77% with respect to the historical average. Over the past ten years (40 quarters), IMRX's Current Ratio was at its highest in in the March 2022 quarter at 37.98. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Immuneering Corporation (IMRX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Immuneering Corporation Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Immuneering Corporation (IMRX) Average Current Ratio

How has IMRX Current Ratio performed in the past?

The current Current Ratio of Immuneering Corporation (IMRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Immuneering Corporation (IMRX) Current Ratio vs. Peers

How is IMRX’s Current Ratio compared to its peers?

Immuneering Corporation’s Current Ratio is less than Theseus Pharmaceuticals, Inc. (29.93), less than PMV Pharmaceuticals, Inc. (19.22), less than Cullinan Oncology, Inc. (28.87), less than Enliven Therapeutics, Inc. (14.39), less than Larimar Therapeutics, Inc. (13.10), less than Centessa Pharmaceuticals plc (13.29), less than Celcuity Inc. (14.95), less than Ikena Oncology, Inc. (18.22), less than Replimune Group, Inc. (13.46), greater than Nuvectis Pharma, Inc. (3.17), greater than Lyra Therapeutics, Inc. (3.60), greater than Kronos Bio, Inc. (8.49), greater than Gossamer Bio, Inc. (8.21), greater than Monte Rosa Therapeutics, Inc. (6.56), less than NewAmsterdam Pharma Company N.V. (9.83), greater than Inventiva S.A. (0.95), less than Compass Therapeutics, Inc. (40.74),

Build a custom stock screener for Immuneering Corporation (IMRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immuneering Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immuneering Corporation (IMRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immuneering Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.